HLA-A24 binding cancer antigen peptide derived from livin
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 13, 2009
Grant Date -
Feb 15, 2007
app pub date -
Jul 7, 2004
filing date -
Jul 11, 2003
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention provides a partial peptide consisting of 8-11 contiguous amino acids in the amino acid sequence of livin set forth in SEQ ID NO: 1, which binds to HLA-A24 antigen and is recognized by cytotoxic T cells (CTLs), a polynucleotide encoding the peptide, and cancer vaccine comprising the peptide or the polynucleotide.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully